REGENERON PHARMACEUTICALS, INC. (NASDAQ:REGN)
595.40 USD 
+4.27 (+0.72%)
Delayed Price / Updated:
4:00 PM EDT, Jul 01, 2022 / Add to My Watchlist
Company Information
Financial Snapshot
| Annual | 12/2021FY | 12/2022FY |
|---|---|---|
| Total Revenue | $8.5 B | $16.07 B |
| Net Income | $3.51 B | $8.08 B |
| Quarterly | 9/30/2021 | 12/31/2021 |
| Total Assets | $23.67 B | $25.43 B |
| Total Liabilities | $6.67 B | $6.43 B |
| Operating Margin | 53.50% | 53.31% |
Address and Details
| Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road |
|
| Industry | Pharmaceuticals: Major |
|---|---|
| Sector | Health Technology |
| Employees | 10,368 |
Business Summary
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Company Officers
| Dr. Leonard S. Schleifer | Dr. Leonard S. Schleifer | Dr. George Damis Yancopoulos | ||||||||||||||||||||||||||
| Co-President, Chief Executive Officer & Director | Co-President, Chief Executive Officer & Director | Co-President, Director & Chief Scientific Officer | ||||||||||||||||||||||||||
| Mr. Robert E. Landry | Dr. Andrew J. Murphy | Ms. Patrice Gilooly | Mr. Bob McCowan | Dr. George Damis Yancopoulos | Dr. Neil Stahl | Mr. Arthur Frederick Ryan | Mr. Arthur Frederick Ryan | Ms. Christine A. Poon | Ms. Christine A. Poon | Dr. P. Roy Vagelos | Dr. Leonard S. Schleifer | Dr. Marc Tessier-Lavigne | Dr. Marc Tessier-Lavigne | Dr. Michael S. Brown | Dr. Michael S. Brown | Dr. Joseph L. Goldstein | Dr. Joseph L. Goldstein | Mr. George L. Sing | Mr. George L. Sing | Dr. George Damis Yancopoulos | Dr. Bonnie L. Bassler | Dr. Bonnie L. Bassler | Dr. Huda Y. Zoghbi | Dr. Huda Y. Zoghbi | Dr. N. Anthony Coles | Dr. N. Anthony Coles | Mr. Joseph J. LaRosa | |
| Chief Financial Officer & Executive VP-Finance | Executive Vice President-Research | Senior VP-Quality Assurance & Operations | Chief Information Officer & Senior VP-IT | Co-President, Director & Chief Scientific Officer | Executive VP-Research & Development | Independent Director | Independent Director | Independent Director | Independent Director | Chairman | Co-President, Chief Executive Officer & Director | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Co-President, Director & Chief Scientific Officer | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Secretary, Executive VP & General Counsel |
Revenue, Returns and Ratios
Total Revenue - TTM
;Total|Revenue(Prev%20Qtr)&BAR_VALUE_SUFFIX=B&YAXIS_LABEL_SUFFIX=B&BAR_WIDTH=90&BAR_VALUE_PREFIX=$&YAXIS_LABEL_PREFIX=$)
Ratios
;P/E|Ratio%20(FY);Debt/Equity|Ratio%20(MRQ)&BAR_VALUE_SUFFIX=&YAXIS_LABEL_SUFFIX=&BAR_WIDTH=55&YSEPLINES=2)
Revenue Summary - TTM
Return on Equity vs. Return on Assets
;Return%20on|Assests%20(MRQ)&BAR_VALUE_SUFFIX=%25&YAXIS_LABEL_SUFFIX=%25&BAR_WIDTH=90)
Per Share
;Cash%20Flow%20Per|Share%20(FY)&BAR_VALUE_SUFFIX=&YAXIS_LABEL_SUFFIX=&BAR_WIDTH=55&YSEPLINES=2)
Peer Comparison
| Company Name | Price | EPS (FY) | Annual Dividend | Book Value (FY) | Cash Flow (FY) |
|---|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $595.40 | 74.99 | 0.00 | 181.86 | 9.57 |
Latest News
More Headlines
Latest News
Market Data
Stock Watchlist
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.